Study design and quality of reporting of randomized controlled trials of chronic idiopathic or autoimmune urticaria: review.
BACKGROUND
The recommended first-line therapy of chronic urticaria is second-generation antihistamines, but the modalities of treatment remains unclear. Numerous recommendations with heterogeneous conclusions have been published. We wondered whether such heterogeneous conclusions were linked to the quality of published studies and their reporting.


OBJECTIVE
To review the study design and quality of reporting of randomized control trials investigating pharmacological treatment of autoimmune or idiopathic chronic urticaria.


RESULTS
MEDLINE and EMBASE were searched for pharmacological randomized controlled trials involving patients with chronic autoimmune or idiopathic urticaria, with the main outcome being treatment efficacy. Data were collected on general characteristics of the studies, internal validity, studied treatments, design of the trial, outcome measures and "spin" strategy in interpreting results. Spin was defined as use of specific reporting strategies to highlight that the experimental treatment is beneficial, despite statistically nonsignificant results. We evaluated 52 articles that met our criteria. Patients were reported as blinded in 42 articles (81%) and the outcome assessor was blinded in 37 (71%). A placebo was the only comparator in 13 (25%) studies. The study duration was <8 weeks in 39 articles (75%), with no follow-up after discontinuation of treatment in 37 (71%). In 4 articles (8%), blinding was clear because they described blinding of the outcome assessor, the treatment was not recognizable (identical or double-dummy) or had no major secondary effects, and computed randomization was centralized. The primary outcome was specified in 33 articles (63%) and was a score in 31. In total, 15 different scores were used. A spin strategy was used for 10 of 12 studies with a nonsignificant primary outcome.


CONCLUSIONS
For establishing guidelines in treatment of chronic urticaria, studies should focus on choosing clinically relevant and reproducible primary outcomes, long-term follow-up, limited use of placebo and avoiding spin strategies.
CHRU de Tours, Service de Dermatologie, Tours, France. elodie.lefourn@univ-tours.fr
Elodie
E
Le Fourn
Bruno
B
Giraudeau
Olivier
O
Chosidow
Marie-Sylvie
MS
Doutre
Gérard
G
Lorette
D001327:Autoimmune Diseases / Q000188:drug therapy*; D002908:Chronic Disease; D006801:Humans; D017063:Outcome Assessment, Health Care; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D012107:Research Design; D058028:Research Report / Q000592:standards*; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy* / Q000276:immunology